Ludlow BioVentures Upgrades Research Opinion on Cryoport, Inc. (CYRX), Maintains Price Target of $3.00 per share Last Updated: Nov. 18, 2008 - 7:58am EST
NEW YORK--Ludlow Bio Ventures upgrades research rating on Cryoport, Inc. (OTC: CYRX), a leading supplier of affordable temperature sensitive shipping solutions for the frozen biopharmaceutical industry, maintains B+ rating, and near-term price target to $3.00 per share.
Summary
While most investors have been focusing on the deteriorating markets and global economy, Cryoport has been banging out some big name leads for their CryoPort Express(TM) pilot shipping program. In their recent 10Q report, the Company announced net inventories increased $299,393 (246%), to $421,345 as of September 30, 2008, from $121,952 as of March 31, 2008. The increase in inventories is due to the purchases of raw materials during the six months ended September 30, 2008 for the build-up of dewars in finished goods inventory in anticipation of the full launch of the CryoPort Express® One-Way Shipper System. This indicates the Company has built their inventory to begin potentially taking in contract orders from potential shippers.
The Company have now established potential large named clients for their shipping program, have set in place the logistical shipping platform in India, developed their inventory to fulfill orders, and now waits for their first named contract. The charges have been placed, fuses have been armed, and now the market waits for the green light to move ahead.